Paragon 28
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Paragon 28 sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
Paragon 28: 7 sponsored US clinical trials, 1 recruiting.
Paragon 28 sponsors 7 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 5 completed. The most-studied condition in this pipeline is Avascular Necrosis of the Talus, with 1 trials.
Upper-quartile sponsor footprint
Paragon 28 sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
7 total, page 1 of 1
Patient Specific Talus Spacer Post Approval Study
NCT05364606
Monster Screw System Post-Market Clinical Follow-Up Study
NCT05190159
Grappler Interference Screw Post-Market Collection of Patient Reported Outcome Measures
NCT05190874
Grappler® Interference Screw Post-Market Clinical Follow-Up Study
NCT04893824
Multi-Plane Hallux Valgus Correction With the Phantom® Nail
NCT04084262
An Evaluation Of Healthy Ankle Motion And Morphology
NCT03619382
Early Weight-Bearing After Lapidus Arthrodesis
NCT03257540
Therapeutic Areas
What is open in the Paragon 28 pipeline
1 recruiting of 7 indexed (14% open); 5 completed (71%).
Phase labels are sparse on this sponsor index, so phase mix is not charted here.
Top condition: Avascular Necrosis of the Talus (1 trial), 0 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Paragon 28: open-pipeline peers nationwide
Peers matched on 7 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
Paragon 28 sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 trials (± recruiting share)
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors near 14% open enrollment (± trial volume)
- Academic and Community Cancer Research United · 14% recruiting · 42 trials
- Adaptive Biotechnologies · 14% recruiting · 7 trials
- AgelessRx · 14% recruiting · 7 trials
- Alaska Blind Child Discovery · 14% recruiting · 7 trials
Related
What to do with this Paragon 28 page
7 registered trials is a research-attention snapshot, not an endorsement of Paragon 28 or any single study.
- 1 of Paragon 28's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Avascular Necrosis of the Talus is the condition Paragon 28 studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Avascular Necrosis of the Talus trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Paragon 28 pipeline card: 7 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.